ClinicalTrials.gov
ClinicalTrials.gov Menu

Warfarin and Non-Steroidal Anti-Inflammatory Drugs (NSAID) Customized Alert

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00880932
Recruitment Status : Completed
First Posted : April 14, 2009
Last Update Posted : April 14, 2009
Sponsor:
Information provided by:
University of Pennsylvania

Brief Summary:
The hypothesis is that a newly formatted electronic alert that requires the prescriber to pause and enter a specific "reason for override" on this alert, will cause prescribers in the intervention group to be significantly less likely to prescribe the combination of warfarin and NSAID than prescribers in the control group.

Condition or disease Intervention/treatment Phase
Warfarin and NSAID Behavioral: Electronic Alert Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1865 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Care Provider)
Official Title: The Effect of Customized Alerts Versus Generic Alerts for the Prescription of Warfarin and NSAID
Study Start Date : August 2006
Actual Primary Completion Date : December 2007
Actual Study Completion Date : December 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners
U.S. FDA Resources

Arm Intervention/treatment
Experimental: customized electronic alert
This intervention was not targeted to patients with a disease but to the providers. The intervention was not a drug but a customized electronic alert, requesting the prescriber to specify a "reason for override" whenever the combination drugs of warfarin and NSAID were ordered together.
Behavioral: Electronic Alert
No Intervention: Standard practice
The control group was not patients but the providers. Providers in the control group continued with the standard practice of receiving passive alerts in the form of message boxes warning the provider not to prescribe the combination drugs warfarin and NSAID.



Primary Outcome Measures :
  1. Decreased rate of prescription of the combination of warfarin and NSAID [ Time Frame: 17 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • All resident physicians (RP) and nurse practitioners (NP) involved in inpatient care at two hospitals of the University of Pennsylvania

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00880932


Locations
United States, Pennsylvania
Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center
Phila, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania

Responsible Party: UPenn School of Medicine
ClinicalTrials.gov Identifier: NCT00880932     History of Changes
Other Study ID Numbers: 803787
First Posted: April 14, 2009    Key Record Dates
Last Update Posted: April 14, 2009
Last Verified: April 2009

Keywords provided by University of Pennsylvania:
warfarin
NSAID
The condition is the concomitant prescription of

Additional relevant MeSH terms:
Warfarin
Anti-Inflammatory Agents, Non-Steroidal
Anticoagulants
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents